Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Open accessThe DOI matches its Crossref record; 142 of the 149 references it cites were found in a registry or an index.
Abstract
Approximately 25% of US adults are estimated to have hypertriglyceridemia (triglyceride [TG] level ≥150 mg/dL [≥1.7 mmol/L]). Elevated TG levels are associated with increased cardiovascular disease (CVD) risk, and severe hypertriglyceridemia (TG levels ≥500 mg/dL [≥5.6 mmol/L]) is a well-established risk factor for acute pancreatitis. Plasma TG levels correspond to the sum of the TG content in TG-rich lipoproteins (TRLs; ie, very low-density lipoproteins plus chylomicrons) and their remnants. There remains some uncertainty regarding the direct causal role of TRLs in the progression of atherosclerosis and CVD, with cardiovascular outcome studies of TG-lowering agents, to date, having produced inconsistent results. Although low-density lipoprotein cholesterol (LDL-C) remains the primary treatment target to reduce CVD risk, a number of large-scale epidemiological studies have shown that elevated TG levels are independently associated with increased incidence of cardiovascular events, even in patients treated effectively with statins. Genetic studies have further clarified the causal association between TRLs and CVD. Variants in several key genes involved in TRL metabolism are strongly associated with CVD risk, with the strength of a variant's effect on TG levels correlating with the magnitude of the variant's effect on CVD. TRLs are thought to contribute to the progression of atherosclerosis and CVD via a number of direct and indirect mechanisms. They directly contribute to intimal cholesterol deposition and are also involved in the activation and enhancement of several proinflammatory, proapoptotic, and procoagulant pathways. Evidence suggests that non-high-density lipoprotein cholesterol, the sum of the total cholesterol carried by atherogenic lipoproteins (including LDL, TRL, and TRL remnants), provides a better indication of CVD risk than LDL-C, particularly in patients with hypertriglyceridemia. This article aims to provide an overview of the available epidemiological, clinical, and genetic evidence relating to the atherogenicity of TRLs and their role in the progression of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Proposed pathophysiology of triglyceride-rich lipoproteins in the progression of atherosclerosis. Note: Adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Cardiology] Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648–661,126 Copyright © 2013. Abbreviations: LPL, lipoprotein lipase; TRL, triglyceride-rich lipoproteins; TRL-R, triglyceride-rich lipoprotein remnants.](https://figures.cochat.ai/paper-figures/0257c3040d4b4514b3d59741a7e289ea/triglyceride-rich-lipoproteins-as-a-causal-factor-for-cardiovascular-disease-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon entering the arterial intima, these remnants are selectively retained through binding to extracellular matrix proteoglycans, prolonging their residence time in the subendothelial space. This retention facilitates uptake by resident macrophages via scavenger receptors, without requiring the oxidative modification typical of LDL particles.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic studies and epidemiologic data increasingly implicate remnant lipoproteins as causal contributors to atherogenesis, providing a strong mechanistic and clinical rationale for targeted intervention [8–12].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The elevated cholesterol content per remnant particle, compared to LDL, amplifies their contribution to lipid accumulation and foam cell formation, key early events in plaque development [17].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“It is also worth noting that LDL-C levels are ordinarily estimated by the Friedewald equation.(116) The Friedewald equation is inapplicable for patients with fasting TG .”
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio (GISSI)-Prevenzione Trial showed that in postMI patients, EPA and DHA significantly reduced the risk of reinfarction and death over a 3-year follow-up period.(97) Additionally, in the Japan EPA Lipid Intervention Study (JELIS), the addition o…”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cited by
Items 101–200 of 236
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
Yamazaki, A., Ohkawa, R., Yamagata, Y., Horiuchi, Y., Lai, S.-J., Kameda, T., Ichimura, N., Tohda, S., & Tozuka, M. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0288 · Cited by 21
“Hence, investigating apoC-II and apoC-III transfers between VLDL and HDL to determine their distribution in each lipoprotein, might yield crucial information regarding CVD risk.”
BackgroundInfluentialIqbal, T., & Miller, M. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01527-x · Cited by 15
“, JELIS, REDUCE-IT, CHERRY [38], EVAPORATE) have consistently demonstrated reduction in Curr Cardiol Rep (2021) 23:111 Page 3 of 6 111”
BackgroundShoar, S., Ikram, W., Shah, A. A., Farooq, N., Gouni, S., Khavandi, S., Tabibzadeh, E., & Khavandi, S. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202037 · Cited by 16
“Such a pro-atherosclerotic state is strongly seen in those with hypertriglyceridemia despite being treated with maximally-tolerated statins [14].”
BackgroundTesting Genetic Pleiotropy with GWAS Summary Statistics for Marginal and Conditional Analyses
Deng, Y., & Pan, W. (2017) · Genetics · doi:10.1534/genetics.117.300347 · Cited by 14
“…the primary treatment target to reduce cardiovascular disease (CVD) risk, it has been shown that high triglyceride (TG) level is a possible independent risk factor for CVD, even in patients with treatment-controlled LDL levels (Boekholdt et al. 2012; Sampson et al. 2012; Do et al. 2013; Toth 2016).”
BackgroundMa, W., Wang, Y., Han, X., Zhu, Y., & Liu, N. (2018) · Bioscience Reports · doi:10.1042/bsr20171642 · Cited by 18
Kim, H. Y., Hong, M. H., Kim, K. W., Yoon, J. J., Lee, J. E., Kang, D. G., & Lee, H. S. (2020) · Nutrients · doi:10.3390/nu12123859 · Cited by 13
Overexpression of NgBR inhibits high-fat diet–induced atherosclerosis in ApoE-deficiency mice
Gong, K., Wang, M., Wang, D., Gao, Y., Ma, L., Yang, X., Zhu, X., Chen, S., Zhang, M., Li, H., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000048 · Cited by 12
Kusakabe, T., Yokota, S., Shimizu, M., Inoue, T., Tanaka, M., Ohue‐Kitano, R., Muranaka, K., Yamakage, H., Wada, H., Hasegawa, K., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001303 · Cited by 11
Risk Factors of Atherosclerosis
Tsioufis, C. P., Mantzouranis, E., Kalos, T., Konstantinidis, D., & Tousoulis, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811908-2.00004-0 · Cited by 18
A single 36-h water-only fast vastly remodels the plasma lipidome
Hong, B. V., Rhodes, C. H., Agus, J., Tang, X., Zhu, C., Zheng, J. J., & Zivkovic, A. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1251122 · Cited by 12
“Hypertriglyceridemia is one of the criteria for diagnosing metabolic syndrome (39), and increased circulating TAG is associated with an increased risk of cardiovascular disease (40).”
BackgroundLongitudinal Lipidomic Signature of Coronary Heart Disease in American Indian People
Miao, G., Pechlaner, R., Fiehn, O., Malloy, K., Zhang, Y., Umans, J. G., Mayr, M., Willeit, J., Kiechl, S. J., & Zhao, J. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031825 · Cited by 15
A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Wang, L., Zhang, Q., Wu, Z., & Huang, X. (2024) · Medicine · doi:10.1097/md.0000000000038754 · Cited by 17
“[41] Not only that, RC can act on the cell wall and increase the secretion of cytokines such as tumor necrosis factor-α and interleukin-1 β , [42,43] leading to the induction of apoptosis of endothelial cells, thereby promoting the formation of atherosclerosis.”
BackgroundGrundy, S. M. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_3 · Cited by 17
Zhang, P., Zhang, Z., Li, D., Han, R., Li, H., Ma, J., Xu, P., Qi, Z., Liu, L., & Zhang, A. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107293 · Cited by 14
Motte, A., Gall, J., Salem, J., Dasque, E., Lebot, M., Frisdal, É., Galier, S., Villard, E. F., Bouaziz-Amar, É., Lacorte, J., et al. (2020) · Biomolecules · doi:10.3390/biom10050810 · Cited by 14
“Indeed, in hypertriglyceridemic patients accelerated CETP-mediated CE transfer from HDL preferentially targets chylomicrons and VLDL1, favoring the formation of cholesterol-enriched lipoprotein remnant particles, the well-established leading cause of cholesterol accumulation in arterial wall foam cells [17].”
BackgroundMetabolic syndrome with mortality and major adverse cardiovascular events in an elderly population
Karn, S. K., Zhao, F., Xu, Y., Zhang, Y., Zeng, C., Shaikh, I. I., Singh, S., & Feng, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570191 · Cited by 14
“Some research has con fi rmed that triglycerides are an independent risk factor for cardiovascular disease (53 – 55).”
Abdik, H., Cumbul, A., Hayal, T. B., Abdik, E. A., Taşlı, P. N., Kırbaş, O. K., Baban, D., & Şahin, F. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126736 · Cited by 9
Kong, D., Mai, Z., Chen, Y., Luo, L., Liu, H., Le, Z., Huang, R., Wang, S., Chen, R., Zhou, H., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15121526 · Cited by 15
Bramlage, P., Lanzinger, S., Rathmann, W., Gillessen, A., Scheper, N., Schmid, S. M., Kaltheuner, M., Seufert, J., Danne, T., & Holl, R. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12783 · Cited by 11
“This atherogenic lipid triad can be present even in the absence of elevated LDL cholesterol levels.(1,4,5) In general, strategies for reducing CV risk focus on lowering LDL cholesterol.”
BackgroundIbi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R. W., Rensen, P. C. N., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.015 · Cited by 10
“In addition to LDL-C, TG-rich lipoproteins (TRLs) have recently been identified as an independent additional risk factor for CVD [6 – 8].”
Jayaraman, S., Pérez, A., Miñambres, I., Sánchez‐Quesada, J. L., & Gursky, O. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159064 · Cited by 13
Therapeutic silencing of FSP27 reduces the progression of atherosclerosis in Ldlr–/– mice
Rajamoorthi, A., Lee, R. G., & Baldán, Á. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.045 · Cited by 9
“Accelerated secretion of VLDL particles is a fundamental property of atherogenic dyslipidemia, which ultimately results in elevated numbers of atherogenic VLDL remnants and LDL particles [30,31].”
Gutstein, A. S., & COPPLE, T. M. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12535 · Cited by 10
“…are independently associated with increased incidence of cardiovascular events, and recent data report that TG-rich lipoproteins play a causal role in the development and progression of atherosclerosis via multiple direct and indirect mechanisms (Figure 1) (Toth, 2016; Watts, Ooi, & Chan, 2013).”
BackgroundHansson, P., Holven, K. B., Øyri, L. K. L., Brekke, H. K., Gjevestad, G. O., Thoresen, M., & Ulven, S. M. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519001429 · Cited by 10
Wolska, A. T., & Remaley, A. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818277-2.00009-1 · Cited by 9
Combined Dyslipidemia in Children and Adolescents
Kavey, R.-E. W. (2016) · Cited by 9
Xiaomei, Z., & Xiaoyan, F. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.07.032 · Cited by 17
Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension
Kazibwe, R., Jehopio, J., Schaich, C. L., Rikhi, R. R., Mirzai, S., Chevli, P. A., Namutebi, J. H., Chebrolu, S., O'Connor, S., Yeboah, J., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.05.006 · Cited by 12
Geng, L., Zong, W., Liu, L., Wu, J., & Pang, J. (2022) · Bioengineered · doi:10.1080/21655979.2021.2019878 · Cited by 9
“It is well known that lowdensity lipoproteins (LDL) and apolipoprotein B (apoB) are involved in the formation of AS, which is mainly caused by a disruption of lipid metabolism [42,43], and LDL levels in plasma have become a vital factor in assessing the risk of CVD and have therapeutic effects [44,45].”
BackgroundSun, C., Brisson, D., Gaudet, D., & Ooi, T. C. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.09.006 · Cited by 9
The Association of Upper Body Obesity with Insulin Resistance in the Newfoundland Population
Youssef, S., Nelder, M., & Sun, G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115858 · Cited by 8
Association Between Nutrients and Cardiovascular Diseases
Shakarami, A. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x263414231101095310 · Cited by 10
“TGRL leads to endothelial dysfunction by inducing oxidative stress and inflammation mediated by increased production of TNF-α, IL-6, Il-8 IL-1β and proatherogenic adhesion molecules [112, 113].”
Li, Z., Lan, X., Jiang, X., Wang, Q., Ma, Z., & He, Z. (2018) · Analytical Methods · doi:10.1039/c8ay01620h · Cited by 6
Chatterjee, S. (2018) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000180 · Cited by 7
Qi, Y., Li, Y., Wang, Z., Wang, X., Meng, H., Li, W., Chen, D.-C., Li, M., Liu, J., & An, S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00626-7 · Cited by 7
“Therefore, HTG has a direct effect on atherosclerosis, increasing the risk of major cardiovascular events [11].”
BackgroundYoshimura, M., Umemoto, S., Kawano, R., Hiromoto, M., Yamada, M., Fujimura, T., Tanaka, M., Nao, T., Miura, T., & Yano, M. (2021) · International Heart Journal · doi:10.1536/ihj.21-015 · Cited by 7
Wang, Y., Song, X., Zhuang, L., Lang, H., Yu, L., Yan, X., & He, Z. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121317 · Cited by 7
Grundy, S. M. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_3 · Cited by 7
Bae, S. S., Shahbazian, A., Wang, J. P., Markovic, D., Leon, T. D., Lee, Y., Reddy, S. T., & Charles‐Schoeman, C. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03520-z · Cited by 8
“Circulating triglyceride-rich lipoproteins enhance endothelial inflammation and promote ICAM-1 and VCAM-1 expression [34, 35], and if occurring in microvessels in the lungs, this could be a potential mechanistic association between triglycerides and ILD.”
Xu, J. Q., Zhu, L., Xie, Y., Zhang, M., Xiao, Z., Su, R., Wen, T., & Liu, L. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230328110215 · Cited by 6
Yang, S., Zhou, W., Dimitriadis, E., & Menkhorst, E. M. (2025) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2025.101654 · Cited by 6
Joshi, R., Wannamethee, S. G., Engmann, J., Gaunt, T. R., Lawlor, D. A., Price, J. F., Papacosta, O., Shah, T., Tillin, T., Whincup, P. H., et al. (2020) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563220961753 · Cited by 6
Soohoo, M., Hashemi, L., Hsiung, J., Moradi, H., Budoff, M. J., Kovesdy, C. P., Kalantar‐Zadeh, K., & Streja, E. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022988 · Cited by 7
“28,29 For non-ASCVD events, a similar explanation of triglyceride-rich lipoprotein accumulation in the arterial wall as well as in the heart muscle, leading to cardiomyopathy, has been suggested in prior studies evaluating triglycerides and heart failure.”
Khalifeh, M., Santos, R. D., Oskuee, R. K., Badiee, A., Aghaee‐Bakhtiari, S. H., & Sahebkar, A. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101197 · Cited by 7
Liu, X., Yang, Y., Kang, F., Li, J., Zhou, M., Ma, X., Yu, T., Zhang, T., & Xue, F. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.058 · Cited by 5
Kwon, Y., Lee, S., Lee, H. S., & Lee, J. (2021) · Nutrients · doi:10.3390/nu13093008 · Cited by 9
Health effects of omega-3 polyunsaturated fatty acids in common diseases
Jia, G., Qiong, Z., & Yonghua, W. (2021) · International Food Research Journal · doi:10.47836/ifrj.28.6.01 · Cited by 8
“6 mmol/L or ≥ 500 mg/dL) is a well-established initiation factor for secondary diseases (Toth, 2016).”
BackgroundInfluentialLiu, Y., Zhang, F., Han, X., Xu, N., Yu, Z., Qige, W., Jianan, W., Bing-jiu, L., & Zhang, Y. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20230814.002 · Cited by 5
Associations between remnant cholesterol levels and mortality in patients with diabetes
Pan, D., Xu, L., Zhang, L., Shi, D.-Z., & Guo, M. H. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.712 · Cited by 6
Corbin, L. J., Hughes, D. A., Chetwynd, A. J., Taylor, A. E., Southam, A. D., Jankevics, A., Weber, R. J. M., Groom, A., Dunn, W. B., & Timpson, N. J. (2020) · Metabolomics · doi:10.1007/s11306-020-01689-9 · Cited by 5
“2019; Toth 2016).”
Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
Maki, K. C., Benes, L. B., & Dicklin, M. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_16 · Cited by 8
Chen, L., Zhang, S., Sun, X., McDonald, J. D., Bruno, R. S., & Zhu, J. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c01009 · Cited by 5
Bogari, N. M., Babalghith, A. O., Bouazzaoui, A., Aljohani, A., Dannoun, A. I., ElKhateeb, O. E., Amin, A. A., Bogari, M. K., Mazhar, A. A., Porqueddu, M., et al. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.11.007 · Cited by 5
“These genes have various roles in regulating the metabolism of triglyceride-rich lipoproteins (TRLs) and low-density lipoproteins (LDLs), thus underlining their roles in causing CAD (Toth, 2016).”
Periconceptional Mediterranean Diet during Pregnancy on Children’s Health
Çobanoğulları, H., Ergören, M. Ç., Dündar, M., Bertelli, M., & Tulay, P. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2748 · Cited by 7
“Undernutrition of fetuses in middle to late gestation results in disappropriate fetal growth, and leads to coronary heart disease [79, 80].”
BackgroundVlacho, B., Julve, J., Genua, I., Fernández‐Camins, B., Real, J., Franch‐Nadal, J., Mauricio, D., & Ortega, E. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.195 · Cited by 6
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Zhang, P., Ma, J., Li, D., Li, Q., Qi, Z., Xu, P., Liu, L., Li, H., & Zhang, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0101 · Cited by 4
“39 Subsequently, oxidized FFAs and TRLs induce endothelial expression of ILs ( i.e. , IL-1, IL-6), cytokines ( i.e. , TNF-a ), and proatherogenic adhesion molecules ( i.e. , intracellular adhesion molecule-1, vascular cell adhesion molecule-1), all of these play a significant role in atherosclerosis.”
Kawahara, Y., Yamashita, T., Ohta, Y., Sato, K., Tsunoda, K., Takemoto, M., Hishikawa, N., Eguchi, J., & Abe, K. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.052 · Cited by 4
“hydrolyzed into intermediate-density lipoprotein (IDL) by LPL in a manner similar to the exogenous pathway described above [6].”
BackgroundInfluentialAlam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
Self-citationCurrent approaches in CRISPR-Cas system for metabolic disorder
Arora, Y., Priya, Kumar, M., & Kumar, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.016 · Cited by 3
Dhananjaya, H., Jog, H., Gupta, S., Mahadevan, A., Chauhan, S., & Desai, R. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i5.117846 · Cited by 5
Zheng, H., Chen, G., Huo, Z., Lan, Y., Wang, Y., Fu, P., Wu, W., Zheng, H., Wu, K., Huang, Z., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045376 · Cited by 5
Elbahloul, M. A., Elgadi, A. T., Fayed, H., Ramadan, M., Kasser, M. E., Hussein, A., Amine, H., & Labieb, F. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003264 · Cited by 3
“…in low-density lipoprotein cholesterol and triglyceride-rich lipoprotein levels were significantly associated with an increased risk of cardiovascular disease, especially coronary heart disease, which indicates a causal association between dyslipidemia and cardiovascular disease [ 2 , 7-10 ] .”
The Effect of Triglyceride Concentration on Attainment of Lipid Targets in Patients with Diabetes
Cartier, L.-J., Collins, C., Lagacé, M., & Douville, P. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.12.006 · Cited by 3
Sasmana, I. G. A. P., Rahadi, P. N. K., Devy, A. A. T., Dewi, P. A. S., Supadmanaba, I. G. P., & Wihandani, D. M. (2023) · Indonesia Journal of Biomedical Science · doi:10.15562/ijbs.v17i1.455 · Cited by 8
Takeda, Y., Furuhashi, M., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., Kumashiro, N., & Sakurai, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1549687 · Cited by 5
“In addition, the favorable impact of pema fi brate on insulin resistance may be also involved in the reduction of dietary fatty acids via its effect on lipoprotein lipase (38, 42).”
Liu, Y., Sequeira, I. R., Ko, J., Shamaitijiang, X., Skudder‐Hill, L., & Petrov, M. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70077 · Cited by 4
Lee, V. Y., Rutherfurd-Markwick, K. J., & Ali, A. (2017) · Journal of Sports Sciences · doi:10.1080/02640414.2017.1306651 · Cited by 3
“Furthermore, high CHO intake is associated with increased fasting triglyceride (TG) levels (Brunner, Wunsch, & Marmot, 2001) and may contribute to an increase in the risk of cardiovascular disease (Toth, 2016).”
BackgroundPervjakova, N., Kukushkina, V., Haller, T., Kasela, S., Joensuu, A., Kristiansson, K., Annilo, T., Perola, M., Salomaa, V. V., Jousilahti, P., et al. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0020 · Cited by 4
Toroghi, M. K., Bosley, J., Powell, L. M., Zhang, Y., Yang, F., Pu, X., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12694 · Cited by 2
Panhuis, W. I. H., Thiemann, E., van Dijk, D. M. A. H., Been, B., Jarrett, K. E., Meurs, A., Kooijman, S., Hovingh, M. V., Modder, M., van Os, B. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx3794 · Cited by 2
“Uniquely, however, IC7Fc simultaneously robustly lowered plasma TG and non-HDL cholesterol levels, which are both independent risk factors for the development of atherosclerotic CVD ( 4 , 38 ).”
Effect of avocado seed extract on lipid profile and atherogenic index in cyclosporine-treated rats
Babatola, L. J., Adebayo, A. A., Ifijeh, J., & Oboh, G. (2023) · Journal of Current Biomedical Research · doi:10.54117/jcbr.v3i1.1 · Cited by 2
Nuevos enfoques en el riesgo cardiovascular residual. Introducción
Zamorano, J. L., & Cequier, A. R. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00007-9 · Cited by 2
Qiu, L., Xu, F., & Dong, B. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s487993 · Cited by 3
“11,12 13–15 In a retrospective cohort study involving patients with acute pancreatitis, it was found that lower HDL-C levels were significantly associated with poorer clinical outcomes, including extended hospital stays.”
Wei, Y., & Liang, H. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2534017 · Cited by 2
“…the promotion of inflammatory mediator expression, which may contribute to endothelial inflammation. additionally, these lipoproteins have been demonstrated to activate pro-coagulation and pro-apoptotic signaling pathways, associated with vascular injury and the progression of atherosclerosis [25].”
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
AVALIAÇÃO DO PERFIL LIPÍDICO EM ADULTOS NO SUL DO BRASIL
Ribeiro, C. S. P., Cademartori, B. G., & Rocha, A. (2016) · Saúde (Santa Maria) · doi:10.5902/2236583421708 · Cited by 2
Prevalência de adesão medicamentosa em pacientes com doença arterial coronariana crônica
Sobral, P. D., Gomes, E. T., Carvalho, P. D. O., Godoi, E. T. A. M., & de Oliveira, D. C. (2020) · Enfermagem Brasil · doi:10.33233/eb.v19i2.2137 · Cited by 4
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Galier, S., Darabi, M., Ma, F., Materne, C., Guillas, I., Goff, W. L., Kontush, A., & Guérin, M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034770 · Cited by 1
Hu, X., Ma, G., Wang, X., Lin, J., Wang, T., & Chen, G. (2025) · Food, Nutrition and Health. · doi:10.1007/s44403-025-00024-1 · Cited by 1
“Hyperlipidemia increases the risk of forming foam cells and atherosclerotic plaques, subsequently elevating the risk of cardio-vascular diseases, stroke, and other metabolic problems [8, 9].”
Carmona‐Maurici, J., Eskubi-Turró, I., Viñas, A., Ricart-Jané, D., López-Tejero, M. D., Amigó, N., Bermúdez-López, M., Baena‐Fustegueras, J. A., Peinado‐Onsurbe, J., & Pardina, E. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10696-x · Cited by 1
“They can more easily penetrate the arterial wall and undergo oxidation [36].”
Bermúdez-López, M., Nogales, P., Martí-Antonio, M., Castro-Boqué, E., Lamo, V. M. D., Beà-Menchón, L., Lima, S. L., Porrini, E., Salguero, X. S., Jové, M., et al. (2026) · Laboratory Animal Research · doi:10.1186/s42826-026-00274-w · Cited by 1
“Elevated levels of VLDLs, IDLs, and their remnants accelerate atherosclerosis progression by promoting cholesterol deposition within the arterial wall [74, 75].”
Association between remnant cholesterol and peripheral artery disease from multiple perspectives
Meng, W., Wang, C., Xu, Z., Qiu, Z., Wang, H., Gu, Y., & Zhu, T. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120784 · Cited by 2
Early atherogenesis: In search of etiology
Brown, P. A. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200650 · Cited by 1
“TLRs have a triglyceride and cholesterol ester core, as well as phospholipids, free cholesterol, and Apos within a surface monolayer [89].”
Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
“Elevated TGs are associated with elevated TG-rich lipoproteins, which may contribute to atherosclerosis by a variety of mechanisms, including infl ammation, coagulation, endothelial dysfunction, foam cell formation, and plaque formation/progression (see Proposed mechanisms of TG-rich lipoprotein particles in atheroscl…”
Zhao, A., Chong, Y., Zhong, H., Ma, J., Zhang, H., Luo, Z., Li, G., & Luo, X. (2017) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe.2017.00008 · Cited by 1
“For example, they directly contribute to intimal cholesterol deposition and are also involved in the activation and enhancement of several proinflammatory, proapoptotic, and procoagulant pathways (9).”
BackgroundWiggins, B. S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001132 · Cited by 2
Bachri, M. S., Anita, W. Y., Yuliani, S., Widyaningsih, W., Sofia, V., & Estiningsih, D. (2023) · Farmasains Jurnal Ilmiah Ilmu Kefarmasian · doi:10.22236/farmasains.v10i1.10407 · Cited by 1
Okamoto, A., Yokokawa, H., Nagamine, T., Goto, K., Fukuda, H., Hisaoka, T., & Naito, T. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01872-w · Cited by 1
The approach to triglyceride levels in patients with coronary heart disease
Shani, I., & Elis, A. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.004 · Cited by 1
Cytotoxic Effect of Triglycerides via Apoptotic Caspase Pathway in Immune and Non-immune Cell Lines
Lim, J., Yang, E. J., & Chang, J. H. (2019) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2019.25.1.66 · Cited by 1
“- 71 - 주로 염증 질환에 초점을 맞추어 대식세포, 단핵구 또는 T 림프구 등 면역계 세포에 대한 연구가 주를 이루었다 (Son et al., 2013; Toth, 2016).”
Thyroid, Lipids, and Risk of Atherosclerosis
Brenta, G., & Schreier, L. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-36871-5_19 · Cited by 2
Mathis, C., Smart, D. J., Xia, W., Phillips, B. W., Peitsch, M. C., Szostak, J., Poussin, C., & Luettich, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820490-0.00022-5 · Cited by 2
Bıyık, İ., Keskin, F., & Saz, N. (2021) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.38.2.9 · Cited by 2
“Some studies reported that triglyceride-rich lipoproteins as a causal factor for cardiovascular disease (Toth, 2016).”
BackgroundHitsumoto, T. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4509 · Cited by 1
“Several studies have emphasized the importance of serum lipid parameters, apart from LDL-C, in the occurrence of CVD events [38-40].”
BackgroundGrundy, S. M. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_3-2 · Cited by 2
Genkel, V. V., Кузнецова, А. С., Pykhova, L., Никушкина, К. В., Savochkina, A. Y., Dolgushin, I. I., & Иосифович, Ш. И. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220427094330 · Cited by 1
Algae cultivation for biomedical applications: Current scenario and future direction
Kaur, A., Kaur, G., Reetu, & Rai, M. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90476-6.00009-1 · Cited by 2
Metadata
- Authors
- Toth, P.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Toth, Peter
- ORCID
- Toth, Peter
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 12
- Pages
- 171
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC4866746
- OpenAlex
- W2345841042
- Cited by
- 237
- References
- 149
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 11 · 2023: 18 · 2022: 27 · 2021: 34 · 2020: 29 · 2019: 22 · 2018: 29 · 2017: 22 · 2016: 8
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglyceride-rich lipoproteins, hypertriglyceridemia, cardiovascular risk, atherosclerosis, VLDL, chylomicrons, acute pancreatitis, non-HDL cholesterol, genetic variants, statin therapy, pro-inflammatory pathways, LDL cholesterol
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Phenotype, Risk Factors, Triglycerides, Hypertriglyceridemia, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment, Genetic Predisposition to Disease, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.